Kiora Pharmaceuticals (Kiora Pharmaceuticals) Days Inventory : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Kiora Pharmaceuticals Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Kiora Pharmaceuticals's Average Total Inventories for the three months ended in Dec. 2023 was $0.00 Mil. Kiora Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Kiora Pharmaceuticals's Days Inventory or its related term are showing as below:

KPRX's Days Inventory is not ranked ^*
in the Biotechnology industry.
Industry Median: 192.335
* Ranked among companies with meaningful Days Inventory only.

Kiora Pharmaceuticals's Days Inventory stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Kiora Pharmaceuticals Days Inventory Historical Data

The historical data trend for Kiora Pharmaceuticals's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiora Pharmaceuticals Days Inventory Chart

Kiora Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

Kiora Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Kiora Pharmaceuticals's Days Inventory

For the Biotechnology subindustry, Kiora Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiora Pharmaceuticals's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiora Pharmaceuticals's Days Inventory distribution charts can be found below:

* The bar in red indicates where Kiora Pharmaceuticals's Days Inventory falls into.

Kiora Pharmaceuticals Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Kiora Pharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Kiora Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Kiora Pharmaceuticals (NAS:KPRX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Kiora Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Kiora Pharmaceuticals's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Kiora Pharmaceuticals Days Inventory Related Terms

Thank you for viewing the detailed overview of Kiora Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiora Pharmaceuticals (Kiora Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiora Pharmaceuticals Inc (NAS:KPRX) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

7EY0:Germany

Address

332 Encinitas Blvd, Suite 102, Encinitas, CA, USA, 92024

Website

https://www.kiorapharma.com

Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages.

Executives

Carmine N. Stengone	director	10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Melissa Tosca	officer: EVP of Finance	C/O KIORA PHARMACEUTICALS, INC., 1371 EAST 2100 SOUTH, SUITE 200, SALT LAKE CITY UT 84105
Susan L. Drexler	officer: Interim CFO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Erin Parsons	director	97 WILLISTON RD, BROOKLINE MA 02445
David Hollander	director	C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703
Brian M. Strem	director, officer: President and CEO	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Eric Joseph Daniels	officer: Chief Development Officer	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Aron Shapiro	director	C/O EYEGATE PHARMACEUTICALS INC., 271 WAVERLY OAKS RD., STE 108, WALTHAM MA 02452
Kenneth L Gayron	director	75 NETWORK DRIVE, BURLINGTON MA 34212
Franz Obermayr	officer: Acting CEO	C/O EYEGATE PHARMACEUTICALS, INC., 271 WAVERLEY OAKS ROAD, SUITE 108, WALTHAM MA 02452
Bernard Malfroy-camine	director	C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110
Thomas Hancock	director	C/O BURNS & LEVINSON LLP, 125 SUMMER STREET, BOSTON MA 02110